Analysis of the Evolution of Pandemic Influenza A(H1N1) Virus Neuraminidase Reveals Entanglement of Different Phenotypic Characteristics.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
11 05 2021
Historique:
entrez: 12 5 2021
pubmed: 13 5 2021
medline: 16 11 2021
Statut: epublish

Résumé

The influenza A virus (IAV) neuraminidase (NA) is essential for virion release from cells and decoy receptors and an important target of antiviral drugs and antibodies. Adaptation to a new host sialome and escape from the host immune system are forces driving the selection of mutations in the NA gene. Phylogenetic analysis shows that until 2015, 16 amino acid substitutions in NA became fixed in the virus population after introduction in the human population of the pandemic IAV H1N1 (H1N1pdm09) in 2009. The accumulative effect of these substitutions, in the order in which they appeared, was analyzed using recombinant proteins and viruses in combination with different functional assays. The results indicate that NA activity did not evolve to a single optimum but rather fluctuated within a certain bandwidth. Furthermore, antigenic and enzymatic properties of NA were intertwined, with several residues affecting multiple properties. For example, the substitution K432E in the second sialic acid binding site, next to the catalytic site, was shown to affect catalytic activity, substrate specificity, and the pH optimum for maximum activity. This substitution also altered antigenicity of NA, which may explain its selection. We propose that the entanglement of NA phenotypes may be an important determining factor in the evolution of NA.

Identifiants

pubmed: 33975931
pii: mBio.00287-21
doi: 10.1128/mBio.00287-21
pmc: PMC8262965
pii:
doi:

Substances chimiques

Hemagglutinin Glycoproteins, Influenza Virus 0
Neuraminidase EC 3.2.1.18

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States

Informations de copyright

Copyright © 2021 Dai et al.

Références

J Virol Methods. 2014 Dec 15;210:7-14
pubmed: 25233882
Clin Microbiol Infect. 2016 Dec;22(12):975-983
pubmed: 27424943
Biochim Biophys Acta. 1991 Mar 8;1077(1):65-71
pubmed: 2009295
Glycoconj J. 2007 Dec;24(9):591-604
pubmed: 17805962
Science. 2009 Oct 30;326(5953):734-6
pubmed: 19900932
PLoS Pathog. 2020 Aug 27;16(8):e1008816
pubmed: 32853241
PLoS Pathog. 2018 Aug 13;14(8):e1007233
pubmed: 30102740
Clin Chim Acta. 1991 May 15;198(3):183-93
pubmed: 1716184
Cell Rep. 2019 Jun 11;27(11):3284-3294.e6
pubmed: 31189111
Influenza Other Respir Viruses. 2014 Mar;8(2):235-42
pubmed: 24118862
J Biol Chem. 1979 Feb 10;254(3):789-95
pubmed: 83994
J Biol Chem. 2011 Feb 18;286(7):5868-75
pubmed: 21173148
Virus Res. 2001 Nov 5;79(1-2):177-85
pubmed: 11551658
Nat Commun. 2015 Feb 10;6:6114
pubmed: 25668439
Science. 2019 Oct 25;366(6464):499-504
pubmed: 31649200
Influenza Other Respir Viruses. 2012 Jul;6(4):245-56
pubmed: 22085243
Nature. 2009 Jun 18;459(7249):931-9
pubmed: 19525932
Structure. 1994 Aug 15;2(8):733-46
pubmed: 7994573
Cell Host Microbe. 2019 Dec 11;26(6):729-738.e4
pubmed: 31757767
Science. 2006 Apr 21;312(5772):399
pubmed: 16556800
J Virol. 2016 Sep 29;90(20):9457-70
pubmed: 27512075
Vaccine. 2012 Dec 7;30(51):7348-52
pubmed: 23063828
Antiviral Res. 2011 Sep;91(3):288-91
pubmed: 21722670
Biologicals. 2001 Mar;29(1):27-37
pubmed: 11482890
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
J Infect Dis. 2015 Oct 15;212(8):1191-9
pubmed: 25858957
Cell Host Microbe. 2019 Dec 11;26(6):715-728.e8
pubmed: 31757769
Nat Struct Mol Biol. 2010 Oct;17(10):1266-8
pubmed: 20852645
Acta Crystallogr D Biol Crystallogr. 2006 Sep;62(Pt 9):947-52
pubmed: 16929094
J Gen Virol. 1994 Feb;75 ( Pt 2):381-8
pubmed: 8113759
Nat Biotechnol. 2008 Jan;26(1):107-13
pubmed: 18176555
Nature. 2006 Mar 23;440(7083):435-6
pubmed: 16554799
J Virol. 2010 Feb;84(3):1597-606
pubmed: 19939933
J Virol. 2013 Sep;87(17):9904-10
pubmed: 23824816
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14264-9
pubmed: 21825167
mBio. 2018 Apr 3;9(2):
pubmed: 29615508
PLoS One. 2013 May 16;8(5):e64439
pubmed: 23696893
J Virol. 2017 Apr 13;91(9):
pubmed: 28202753
J Virol. 2015 Oct 14;90(1):117-28
pubmed: 26468531
Nat Microbiol. 2019 Jun;4(6):1024-1034
pubmed: 30886361
J Virol. 2008 Nov;82(21):10493-501
pubmed: 18715929
Sci Rep. 2016 Nov 09;6:36826
pubmed: 27827454
J Virol. 2014 Aug;88(15):8278-96
pubmed: 24829341
J Am Chem Soc. 2010 Mar 10;132(9):2883-5
pubmed: 20155919
J Mol Biol. 2006 Feb 3;355(5):1143-55
pubmed: 16343533
J Virol. 2020 Jan 31;94(4):
pubmed: 31748388
PLoS Pathog. 2019 Jun 10;15(6):e1007860
pubmed: 31181126
J Virol. 2012 Sep;86(17):9221-32
pubmed: 22718832
J Virol. 2013 Aug;87(16):9290-300
pubmed: 23785204
J Virol. 2005 Sep;79(18):11705-15
pubmed: 16140748
Biochemistry (Mosc). 2015 Jul;80(7):872-80
pubmed: 26542001
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11808-12
pubmed: 9342319
J Virol. 1997 Sep;71(9):6706-13
pubmed: 9261394
J Virol. 2018 Jan 30;92(4):
pubmed: 29167342
Protein Sci. 1994 Oct;3(10):1687-96
pubmed: 7849585
J Mol Biol. 1992 Sep 5;227(1):122-48
pubmed: 1381757
Glycobiology. 2011 Aug;21(8):988-93
pubmed: 21863598
J Biol Chem. 1987 Feb 5;262(4):1596-601
pubmed: 3805045
Sci Rep. 2016 Apr 13;6:24402
pubmed: 27072615
J Virol. 2018 Sep 26;92(20):
pubmed: 30089692
Biol Pharm Bull. 2015;38(6):817-26
pubmed: 26027822
FEBS J. 2020 Dec 14;:
pubmed: 33314755
FEBS Lett. 1975 Feb 15;50(3):296-9
pubmed: 1116600
Biochim Biophys Acta. 1958 May;28(2):444-5
pubmed: 13535748
EMBO J. 1992 Jan;11(1):49-56
pubmed: 1740114
Trends Microbiol. 2020 Jan;28(1):57-67
pubmed: 31629602
mBio. 2019 Apr 9;10(2):
pubmed: 30967460
Nat Microbiol. 2019 Dec;4(12):2565-2577
pubmed: 31451775
Arch Virol. 2009;154(6):945-57
pubmed: 19458903
PLoS Pathog. 2014 Apr 03;10(4):e1004065
pubmed: 24699865
Angew Chem Int Ed Engl. 2012 Feb 27;51(9):2221-4
pubmed: 22281708
J Virol. 1999 Nov;73(11):9679-82
pubmed: 10516084

Auteurs

Meiling Dai (M)

Virology Section, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.

Wenjuan Du (W)

Virology Section, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.

Carles Martínez-Romero (C)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Tim Leenders (T)

Department Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.

Tom Wennekes (T)

Department Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.

Guus F Rimmelzwaan (GF)

Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany.

Frank J M van Kuppeveld (FJM)

Virology Section, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.

Ron A M Fouchier (RAM)

Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.

Adolfo Garcia-Sastre (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Erik de Vries (E)

Virology Section, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.

Cornelis A M de Haan (CAM)

Virology Section, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands c.a.m.dehaan@uu.nl.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH